Ergomed
Ergomed provides global clinical research, pharmacovigilance and GxP audit services to pharma and biotech, with a focus on oncology and rare disease trials.
Ergomed is a global provider of specialized clinical research services, delivering end-to-end clinical development, pharmacovigilance and GxP audit solutions to pharmaceutical and biotechnology companies. Founded in 1997 and headquartered in Guildford, UK, with a US headquarters in Raleigh, North Carolina, the company employs more than 2,900 professionals and operates across approximately 100 countries.
The group's work is organised through specialised subsidiaries. Ergomed Clinical Research provides end-to-end clinical development and clinical trial management services; PrimeVigilance delivers pharmacovigilance services; and ADAMAS Consulting covers GxP audit and consulting. Ergomed CARE™, a proprietary solution, supports patient-centric trial management.
Ergomed concentrates on demanding therapeutic areas, notably oncology and rare diseases. The company reports having conducted more than 330 oncology studies and over 200 rare disease trials, and to have managed upwards of 600 Phase I–IV clinical trials. Its pharmacovigilance operations process more than 275,000 patient cases annually.
The organisation describes itself as having a flat structure intended to support agility and responsiveness, with a distributed, global workforce of experienced professionals and a patient-centric approach to trial management.